SCHEMBL7010381

SCHEMBL7010381

CC(C#N)CCc1ccc(O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.48
ESR2 Q92731 5/20 0.48
OPRK1 P41145 2/20 0.46
MEN1 O00255 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP2C9 P11712 1/20 0.46
KDM4E B2RXH2 3/20 0.45
ADRB2 P07550 2/20 0.45
CA2 P00918 2/20 0.43
SLC6A2 P23975 3/20 0.43
SIGMAR1 Q99720 2/20 0.43
ADRA2A P08913 2/20 0.43
HTR3A P46098 2/20 0.43
SLC22A1 O15245 1/20 0.43
CA12 O43570 1/20 0.43
EGFR P00533 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7128508 0.83 OPRM1 (0.47) ESR1ESR2OPRK1MEN1CYP1A2
SCHEMBL7717163 0.81 TSHR (0.39) CYP1A2ALDH1A1HTTTSHR
SCHEMBL7011495 0.80 ESR1 (0.58) ESR1ESR2MEN1CYP1A2CYP3A4
SCHEMBL14032395 0.80 ESR1 (0.58) ESR1ESR2MEN1CYP1A2CYP3A4
SCHEMBL13900603 0.80 POLB (0.47) OPRK1MEN1CYP1A2KMT2AALDH1A1
SCHEMBL10389823 0.78 ESR1 (0.45) ESR1ESR2OPRK1MEN1CYP1A2
SCHEMBL104626 0.77 ESR1 (0.59) ESR1ESR2OPRK1MEN1CYP1A2
SCHEMBL10389825 0.77 ESR1 (0.46) ESR1ESR2OPRK1MEN1CYP1A2
SCHEMBL13698055 0.75 ESR1 (0.56) ESR1ESR2OPRK1MEN1KMT2A
SCHEMBL13698052 0.75 ESR1 (0.56) ESR1ESR2OPRK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1267874-A2 THERAPEUTIC USES OF PPAR MEDIATORS Aventis Pharma Deutschland GmbH (DE) 2003-01-02 EP disclosed
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
WO-2001066098-A2 THERAPEUTIC USES OF PPAR MEDIATORS AVENTIS PHARMA DEUTSCHLAND GMBH 2001-09-13 WO disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed